Results 61 to 70 of about 77,046 (263)
SARS-CoV-2-Induced Remission of Chemotherapy Resistance B-Cell Non-Hodgkin Lymphoma: A Case Report
Introduction: Investigation on virus-host interaction may provide new clues for antitumor immunotherapy. Case Presentation: In this case report, we describe an unusual case of B-cell non-Hodgkin lymphoma in an aged woman who recovered following SARS-COV ...
Yan Xiao +4 more
doaj +1 more source
Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
Distinct Molecular Pathways Supporting Sjögren Disease Clusters and Disease Progression
Objective Sjögren disease (SjD) is a heterogeneous autoimmune disease. We aimed to investigate blood transcriptomic signatures and disease progression among three recently defined clusters of patients with SjD: (1) B cell active disease with low symptom burden (BALS), (2) high systemic activity (HSA), and (3) low systemic activity with high symptom ...
Sacha E. Silva‐Saffar +6 more
wiley +1 more source
Gene expression profiling in B-cell non-Hodgkin lymphomas
BACKGROUND: Gene expression profiling has become a fundamental tool in cancer diagnosis and management. B-cell non-Hodgkin lymphoma (B-NHL) is a group of malignant neoplasms originating from the lymphoid tissues, mainly the lymph nodes and the gene ...
Renas N. Saleem, Ahmed Khudair Yassin
doaj +1 more source
Peripheral Blood DNA Methylation Changes Precede Lymphoma Diagnosis in Primary Sjögren's Disease
Objective Primary Sjögren's disease (SjD) is a systemic autoimmune disease associated with an increased risk of lymphoma. The molecular mechanisms underlying lymphomagenesis remain poorly understood, and sensitive biomarkers for early identification of patients at high risk of developing lymphoma are lacking.
Hanna Lidberg +2 more
wiley +1 more source
Pathophysiology and molecular aspects of diffuse large B-cell lymphoma
Diffuse large B-Cell lymphoma is the most common subtype of non-Hodgkin lymphoma in the West. In Brazil, it is the fifth cause of cancer, with more than 55,000 cases and 26,000 deaths per year.
Gisele Rodrigues Gouveia +2 more
doaj
Molecular Diagnostics of Aggressive B-Cell Non-Hodgkin Lymphomas
Background: Malignant lymphomas are among the most common hematological neoplasms and include a heterogeneous group of entities characterized by distinct morphology, immunophenotype, genetics, and clinical features.
Valeriia Tsekhovska +4 more
doaj +1 more source
B cell acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL) frequently express CD19, CD20 and CD22 on the cell surfaces. Immunotherapeutic agents including antibodies and chimeric antigen receptor T cells are widely studied in clinical ...
Amandeep Aujla +2 more
doaj +1 more source
The life and legacy of Dr. Carlton G. Smith
Abstract Carlton George Smith, M.Sc., M.D., Ph.D., R.C.N.V.R. (1905–2003) was a Canadian anatomist and professor at the University of Toronto. He was highly regarded as an outstanding teacher, cutting‐edge neuroscience researcher, and accomplished author. Dr. Smith became a member of the AAA in 1938 and joined the prestigious Cajal Club in 1950.
Mikaela L. Stiver, Anne M. R. Agur
wiley +1 more source
While the event‐free survival (EFS) of children treated for acute lymphoblastic leukaemia (ALL) has improved greatly in the last decades, the EFS for patients diagnosed with ALL before the age of one is still under 50%. This outcome further decreases when infants have a rearrangement in the gene encoding histone‐lysine N‐methyltransferase 2A (KMT2A ...
Tirsa de Kluis +5 more
wiley +1 more source

